Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0519030 (Klebsiella)
 21,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Netilmicin (Sch 20569) is an ethyl derivative of gentamicin C(1a) that is active against most Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus isolates. Among 342 clinical isolates tested, all staphylococci; 92% of Escherichia coli, 93% of Klebsiella pneumoniae, and 92% of Enterobacter were inhibited by 0.8 mug or less of netilmicin per ml, but only 78% of P. aeruginosa were inhibited by 3.1 mug or less per ml. Most clinical isolates of enterococci, Serratia marcescens, and Providencia were not inhibited by 3.1 mug of netilmicin per ml. Like other aminoglycosides, the netilmicin in vitro activity was markedly influenced by the growth medium used, with activity decreased by sodium, calcium, and magnesium. Netilmicin was more active at alkaline pH. Addition of magnesium to Pseudomonas or Serratia pretreated with netilmicin produced inhibition of killing. Netilmicin was more active than gentamicin, sisomicin, tobramycin, or amikacin against E. coli and K. pneumoniae. Netilmicin inhibited growth of all gentamicin-resistant isolates of Klebsiella and Citrobacter tested, but only 73% of E. coli; Pseudomonas and Providencia were resistant to netilmicin. Most Serratia (95%) and indole-positive Proteus (83%) isolates were resistant to netilmicin but were inhibited by amikacin.
 ...
PMID:In vitro study of netilmicin compared with other aminoglycosides. 1 Aug 29

Netilmicin, a new aminoglycoside antibiotic, was used to treat 19 patients with urinary tract infection and 5 with systemic infection. The causal organisms were Escherichia coli (in 2), Klebsiella pneumoniae (in 4), Serratia marcescens (in 12) and Pseudomonas aeruginosa (in 7); 1 patient was infected with two of these organisms. All the isolates of causal organisms except one of Serratia were initially sensitive to netilmicin but many were resistant to other aminoglycosides. Sixteen of the urinary tract infections responded to netilmicin therapy, although relapse occurred in three patients. Two of the three patients with musculoskeletal infection responded to combined therapy with surgery and netilmicin; the other patient responded to the same regimen but with carbenicillin added. Netilmicin cured pneumonia in one patient but failed in the other patient with pneumonia, who had leukemia. Superinfection occurred in five patients with urinary tract infection. Adverse reactions to netilmicin were minor. Netilmicin may prove to be a useful agent, particularly for infections due to multiresistant Klebsiella or Serratia, or when prolonged aminoglycoside therapy is required.
 ...
PMID:Therapeutic experience with netilmicin. 10 97

Ninety-two patients with cancer with 100 infectious episodes were treated with netilmicin sulfate, a new aminoglycoside. Netilmicin was administered intravenously, either intermittently or by continuous infusion. The overall cure rate was 60%. Gram-negative bacilli were the most common causative organisms and the response rate for these infections was 32/53 (60%). The most common pathogens were Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Pneumonia, urinary tract infection, and septicemia were the most common types of infection treated and the response rates were 23/47 (49%), 19/21 (90%), and 9/17 (53%), respectively. Nephrotoxicity occurred in ten patients (6%) who had normal renal function initially. Netilmicin is an effective aminoglycoside with a spectrum of antibacterial activity similar to that of gentamicin sulfate and it appears to be less nephrotoxic.
 ...
PMID:Netilmicin in the treatment of infections in patients with cancer. 38 89

The in vitro activity of netilmicin (Sch 20569), a new semisynthetic derivative of gentamicin, was compared with that of gentamicin and amikacin. One hundred and ninety-two clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus were tested using both agar and broth dilution techniques. Netilmicin was comparable to gentamicin, with the following exceptions: (i) for Serratia marcescens and P. aeruginosa, gentamicin was more active than netilmicin; (ii) all strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, and Citrobacter freundii, which were resistant to gentamicin, were susceptible to netilmicin; (iii) some strains of S. marcescens, indole-positive Proteus, and Providencia, which were resistant to gentamicin, were susceptible to netilmicin. Netilmicin was more active than amikacin for all Enterobacteriaceae and S. aureus and equal to amikacin in activity against gentamicin-susceptible strains of P. aeruginosa. All strains of P. aeruginosa, resistant to gentamicin, were also resistant to netilmicin but were susceptible to amikacin. Minimal inhibitory concentrations (MICs) obtained with broth and agar showed no significant differences except for P. mirabilis, where broth MICs were twofold greater than agar MICs, and for P. aeruginosa, where agar MICs were twofold higher than broth MICs. The minimal bactericidal concentration (MBC) was either identical to or within one twofold dilution of the MIC for the strains tested. A 100-fold increase in inoculum size produced less increase in MIC and MBC with netilmicin than with gentamicin or amikacin.
 ...
PMID:In vitro activity of netilmicin, gentamicin, and amikacin. 40 4

An in vitro study of the susceptibility of 201 newly isolated strains of gramnegative bacteria to six aminoglycoside antibiotics (kanamycin, amikacin, gentamicin, tobramycin, sisomicin and netilmicin) was performed by the twofold dilution method in fluid medium. Both the minimal inhibitory concentration and the minimal bacteridical concentration were determined. Overall, tobramycin seemed the most effective of the drugs studied. Netilmicin, the new derivative from sisomicin, compared favourably with the other drugs tested, but may, on theoretical grounds, offer the additional advantage of retained efficacy in the face of developing bacterial resistance. Not unexpectedly, amikacin appeared to be the most promising of the drugs studied in its action against Pseudomonas aeruginosa. Amikacin and netilmicin appeared to be the most effective of this group of antibiotics against Klebsiella species.
 ...
PMID:Sensitivity of gram-negative bacteria to six aminoglycoside antibiotics. 40 54

The inhibitory activity of netilmicin against 500 isolates of gram-negative bacteria was compared with those of gentamicin and tobramycin. Netilmicin was considerably less active than tobramycin and slightly less inhibitory than gentamicin for Pseudomonas aeruginosa but was at least as active against Escherichia coli and Klebsiella pneumoniae as were the other two antibiotics. A few Klebsiella and Serratia isolates resistant to gentamicin and tobramycin were inhibited by netilmicin. All three antibiotics were strongly bactericidal for E. coli, K. pneumoniae and P. aeruginosa but had less lethal activity against the otherwise susceptible Serratia isolates tested. Some necessary precautions in reading minimal inhibitory concentrations on agar media are stressed, and some possible advantages of a 4-h bactericidal test, using a constant antibiotic concentration, are defined.
 ...
PMID:Activity of netilmicin compared with those of gentamicin and tobramycin against enterobacteria and Pseudomonas aeruginosa. 41 Mar 61

A new aminoglycoside antibiotic, netilmicin, was tested against 306 clinical isolates from ill children and compared with sisomicin and gentamicin. Activity against Enterobacteriaceae was similar to that of gentamicin but less than that of sisomicin. Two gentamicin-resistant strains of Enterobacteriaceae (Klebsiella, MIC 6.25 microgram/ml, Escherichia coli, MIC 12.5 microgram/ml) were susceptible to netilimicin (MIC 3.12 microgram/ml). Netilmicin was ineffective against almost all strains of Pseudomonas but active against the majority of strains of Staphylococcus, Neisseria meningitidis and Haemophilus influenzae tested. Disc diffusion sensitivity results correlated in general with the agar dilution test. Netilmicin had little activity against Pseudomonas but may be useful in the treatment of infections due to gentamicin-resistant Enterobacteriaceae.
 ...
PMID:In vitro activity of netilmicin (SCH 20569) against bacterial isolates from ill children. 41 47

Netilmicin, a semisynthetic derivative of sisomicin, was tested in vitro against 600 clinical bacterial isolates. At a concentration of 1.56 mug/ml, over 90% of gram-negative bacilli were inhibited. Netilmicin was substantially more active against isolates of Serratia marcescens and Enterobacter spp. than gentamicin, sisomicin, tobramycin, or amikacin. Isolates of Staphylococcus aureus (both penicillin G susceptible and resistant) were quite susceptible to netilmicin. Most isolates of Klebsiella spp. and Serratia spp. and some of the isolates of Pseudomonas aeruginosa that were resistant to gentamicin proved to be susceptible to netilmicin.
 ...
PMID:In vitro studies on netilmicin, a new aminoglycoside antibiotic. 87 46

Pharmacokinetics and tissue penetration of netilmicin were studied after the use of a single dose (6 mg/kg) given for antibioprophylaxis in colo-rectal surgery. Thirteen patients, scheduled for elective surgery, were given 6 mg/kg IV netilmicin over 30 min, together with 1000 mg IV ornidazole. Netilmicin peak serum concentration (10 min after end of infusion) was 24.4 +/- 3.4 mg/l and trough level (24 h) was 0.9 +/- 0.5 mg/l. Plasma elimination half-life was 409 +/- 70 min, le volume apparent volume of distribution was 38 +/- 101 and total body clearance was 0.07 +/- 0.02 ml/min. Adequate netilmicin levels (5 greater than or equal to CMI 90 of involved pathogens Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus) were obtained in 100 per cent of patients in abdominal wall and epiploid fat, at time of opening, and in colonic wall at time of anastomosis. Adequate levels were obtained at time of closure in abdominal wall and epiploid fat in 92 to 100 per cent of patients. In situation of allergy to beta-lactam antibiotics, the use of netilmicin in combination with ornidazole may be recommended.
 ...
PMID:[Pharmacokinetics and tissue penetration of single-dose netilmicin used for antibiotic prophylaxis during colo-rectal surgery]. 188 84

The action of broad-spectrum antibiotics investigated by disc diffusion method on 636 problem bacteria such as S. aureus, Enterobacter, Klebsiella, Pseudomonas, E. coli, Proteus that isolated from various clinical specimens. The highest and lowest ratio of susceptibility were as follows: S. aureus were found sensitive 90% to Netilmicin, 27% to Piperacillin, Enterobacter species 78% to Netilmicin, 25% to Piperacillin, Klebsiella 69% to Amikacin, 20% to Piperacillin, Pseudomonas 66% to Amikacin, 5% to Amoxicillin-Clavulanic acid, E.coli 68% to Netilmicin and Ceftriaxone, 32% to Piperacillin, Proteus 70% to Netilmicin, 43% to Piperacillin, S.epidermidis 90% to Amoxicillin-Clavulanic acid, 60% to Piperacillin.
 ...
PMID:[Susceptibility of clinically-isolated problem pathogenic bacteria to broad spectrum antibiotics]. 248 44


1 2 Next >>